Armata Pharmaceuticals : Amendment to a previously filed SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 35 )*

Eli Lilly and Company

(Name of Issuer)

Common Stock, Without Par Value

(Title of Class of Securities)

532457-10-8

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

• Rule 13d-1(b)
• Rule 13d-1(c) x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP	532457-10-8
No.

1		NAMES OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
		LILLY ENDOWMENT INC
		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
2		(a)	o
	(b)	o
		SEC USE ONLY
3
		CITIZENSHIP OR PLACE OF ORGANIZATION
4		Indiana
						SOLE VOTING POWER
				5		114,560,599
						SHARED VOTING POWER
				6		0
NUMBER OF			SOLE DISPOSITIVE POWER
SHARES		7
BENEFICIALLY		114,560,599
OWNED BY
		SHARED DISPOSITIVE POWER
	EACH
REPORTING	8
PERSON WITH:		0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

• 114,560,509
  CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

10 o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11 11.9%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12 CO

FOOTNOTES

The percent of class represented is based on 960,130,771 shares of common stock outstanding as of October 21, 2019, as reported on the Issuer's Form 10 Q for the period ended September 30, 2019.

Item 1.

1. Name of Issuer
   Eli Lilly and Company
2. Address of Issuer's Principal Executive Offices Lilly Corporate Center, Indianapolis, Indiana 46285.

Item 2.

1. Name of Person Filing
   This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc. is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.
2. Address of Principal Business Office or, if none, Residence
   The address of the principal business office of Lilly Endowment Inc. is 2801 North Meridian Street, Indianapolis, Indiana 46208.
3. Citizenship Indiana
4. Title of Class of Securities Common Stock, Without Par Value
5. CUSIP Number 532457-10-8

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

1. o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
2. o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
3. o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
4. o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
5. o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
6. o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
7. o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
8. o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
9. o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
10. o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
11. o A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii) (J), please specify the type of institution:

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. Amount beneficially owned: 114,560,599
2. Percent of class: 11.9%
3. Number of shares as to which the person has:
4. 1. Sole power to vote or to direct the vote: 114,560,599
   2. Shared power to vote or to direct the vote: 0
   3. Sole power to dispose or to direct the disposition of: 114,560,599
   4. Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item Certification 10.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and

correct.

	Lilly Endowment, Inc.
Date: January 07, 2020	By: /s/ Diane M. Stenson
	Name: Diane M. Stenson
	Title: Vice President & Treasurer

Footnotes: Item 4: This information is provided as of December 31, 2019.

Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.

Item 4(b): The percent of class represented is based on 960,130,771 shares of common stock outstanding as of October 21, 2019, as reported on the Issuer's Form 10 Q for the period ended September 30, 2019.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)